DADC
PPH icon

D.A. Davidson & Co’s VanEck Pharmaceutical ETF PPH Stock Holding History

D.A. Davidson & Co’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-725
Closed -$46K – 2158
2014
Q3 		$46K Hold
725
– – ﹤0.01% 1443
2014
Q2 		$44K Sell
725
-600
-45% -$35.7K ﹤0.01% 1450
2014
Q1 		$77K Hold
1,325
– – ﹤0.01% 1251
2013
Q4 		$70K Hold
1,325
– – ﹤0.01% 1219
2013
Q3 		$63K Sell
1,325
-200
-13% -$9.48K ﹤0.01% 1067
2013
Q2 		$69K Buy
+1,525
New +$70.5K ﹤0.01% 1009

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $144M AUM 19.29% 1-Year Est. Return
AHS
Aspiriant Holdings S3 Los Angeles, California $233M AUM 3.13% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

D.A. Davidson & Co's PPH Position: Q4 2014 in Review

D.A. Davidson & Co sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2014, closing a stake of 725 shares — an estimated $46K sold.

D.A. Davidson & Co first reported a position in PPH in Q2 2013 and held it in 6 quarters. The position peaked at $77K in Q1 2014. 58 funds tracked by Wall St. Rank hold PPH as of Q4 2014.

  • D.A. Davidson & Co reported no remaining VanEck Pharmaceutical ETF position as of Q4 2014 after selling out during the quarter.
  • D.A. Davidson & Co sold 725 VanEck Pharmaceutical ETF shares in Q4 2014, an estimated $46K.
  • D.A. Davidson & Co first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and held it in 6 quarters.
  • D.A. Davidson & Co's VanEck Pharmaceutical ETF position peaked at $77K in Q1 2014.
  • 58 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2014.

Based on D.A. Davidson & Co's 13F filing for Q4 2014, filed 12 Feb 2015.